CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 244 enrolled
Drug / intervention
Peginterferondrug
Likely dose
Peginterferon 35 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00732641
NCT00732641Phase 3Completed
CompareCT.gov

Phase III Randomized, Prospective Multi-center Trial of PEG-Interferon α-2b as a Maintenance Therapy, Compared to Observation, in Patients With Multiple Myeloma Who Responded to Induction Therapy (Protocol No P01972)

Merck Sharp & Dohme LLC·interventional·Posted Aug 12, 2008·Updated Apr 4, 2017

In Brief

A Phase 3 clinical trial evaluating Peginterferon for Multiple Myeloma. Completed, enrolled 244 participants.

Detailed Summary

This study aims to assess the efficacy of peginterferon α-2b, compared to a control arm not receiving any maintenance treatment, in adult subjects with multiple myeloma who have responded to a prior induction therapy. Peginterferon α-2b will be given once weekly as an injection until disease progression or relapse, or for up to a maximum of 5 years (whichever occurs first).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 12, 2008
Enrollment StartDec 1, 2000
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 9.9 yearsPosted 17.9 years ago

Interventions

Peginterferondrug

Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.